ロード中...
Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach
AIMS: Glycopyrronium bromide (NVA237) is a once-daily long-acting muscarinic antagonist recently approved for the treatment of chronic obstructive pulmonary disease. In this study, we used population pharmacokinetic (PK) modelling to provide insights into the impact of the lung PK of glycopyrronium...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Science Inc
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845310/ https://ncbi.nlm.nih.gov/pubmed/23506208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12118 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|